What is the history of Smith-Lemli-Opitz Syndrome?

Smith-Lemli-Opitz syndrome was first described in 1964 by pediatricians David Smith, Luc Lemli, and John Opitz as a constellation of physical anomalies and intellectual disability. Since then, the understanding of Smith-Lemli-Opitz syndrome has evolved from a purely clinical diagnosis to a well-defined metabolic disorder caused by a deficiency in the enzyme 7-dehydrocholesterol reductase, which impairs cholesterol synthesis.

How was Smith-Lemli-Opitz syndrome first identified?

In 1964, a landmark paper published in the Journal of Pediatrics introduced the medical community to three male patients sharing a distinct pattern of clinical features. The physicians David Smith, Luc Lemli, and John Opitz noticed these patients presented with microcephaly, syndactyly of the second and third toes, and characteristic facial features. At the time of its discovery, Smith-Lemli-Opitz syndrome was categorized strictly by its physical presentation, and the underlying biochemical cause remained a mystery for over three decades.

How did our understanding of the cause evolve?

For many years, clinicians struggled to identify the root cause of Smith-Lemli-Opitz syndrome, leading to various hypotheses regarding its origin. It was not until 1993 that researchers identified the metabolic defect: a deficiency in the enzyme 7-dehydrocholesterol reductase (DHCR7). This breakthrough revealed that the syndrome is an autosomal recessive disorder of cholesterol biosynthesis. This discovery fundamentally changed the diagnostic landscape, moving from subjective clinical observation to objective biochemical testing and molecular genetic confirmation.

What were the major milestones in treatment development?

The identification of the cholesterol synthesis defect opened the door to targeted nutritional therapy. Before this, management for Smith-Lemli-Opitz syndrome was purely supportive. Once the metabolic pathway was understood, physicians began implementing cholesterol supplementation and, in some cases, bile acid therapy to improve growth and neurological outcomes. The evolution of treatment has been marked by several key developments:

• 1964: First clinical description of the syndrome by Smith, Lemli, and Opitz.


• 1993: Identification of the cholesterol biosynthesis defect as the primary driver of the condition.


• 1997: Cloning of the DHCR7 gene, allowing for precise genetic testing and prenatal diagnosis.


• 2000s–Present: Development of standardized protocols for cholesterol supplementation to manage systemic symptoms.

How have technology and advocacy changed the landscape?

Modern genetics has revolutionized the diagnosis of Smith-Lemli-Opitz syndrome. Today, next-generation sequencing allows for rapid identification of mutations in the DHCR7 gene, providing families with definitive answers much earlier in a child's life. Parallel to these scientific leaps, patient advocacy has grown significantly. Within our own community at DiseaseMaps.org, 61 people with Smith-Lemli-Opitz syndrome have connected to share their lived experiences, transforming the journey from one of isolation to one of collective support and shared knowledge.

Next steps

• Consult with a clinical geneticist to discuss genetic testing options and carrier status.


• Speak with a metabolic specialist or endocrinologist familiar with cholesterol biosynthesis disorders.


• Join the DiseaseMaps.org community to connect with other families navigating the daily realities of this condition.


• Stay informed on the latest clinical trials by monitoring the NIH GARD website for updates on research regarding Smith-Lemli-Opitz syndrome.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Smith-Lemli-Opitz syndrome.


• Orphanet: Rare disease database entry for Smith-Lemli-Opitz syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #270400 (Smith-Lemli-Opitz Syndrome).


• Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. J Pediatr. 1964.